Details of the Drug Combinations

General Information of This Drug (ID: DM6SGUB)

Drug Name

Amrubicin DM6SGUB

Synonyms

110267-81-7; Amrubicin [INN]; SCHEMBL119022; AC1L4374; (+-)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione; BC677604; AN-16624; LS-183761; FT-0662134; ( -)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione; (7S,9S)-9-acetyl-9-amino-7-(4,5-dihydroxytetrahydropyran-2-yl)oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione

Indication

Disease Entry	ICD 11	Status	REF
Small-cell lung cancer	2C25.Y	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Amrubicin + Topotecan	DCEFNQ3	Topotecan	Small Cell Lung Cancer (SCLC)	[2]
Amrubicin + Lurbinectedin	DC37XA4	Lurbinectedin	Small Cell Lung Cancer	[3]
Amrubicin + Lurbinectedin	DC8P6ID	Lurbinectedin	Small Cell Lung Cancer (SCLC)	[4]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00547651) AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT01904253) A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
3	ClinicalTrials.gov (NCT06203210) A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
4	ClinicalTrials.gov (NCT05740566) Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer